Compare Boston Scientific Corporation (BSX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Consumer Staples Select Sector SPDR Fund — how do they compare? Boston Scientific Corporation trades at $43.29 (market cap $66.37B), while Consumer Staples Select Sector SPDR Fund trades at $83.83. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | XLP | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | — |
52-Week High | $108.14 | $90.00 |
52-Week Low | $42.63 | $75.61 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $84.58, up 0.55% with a bullish technical signal from moving averages. The ETF holds 36 consumer staples stocks and offers a 2.6% dividend yield. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid market uncertainty, with retail sales hitting 12-month highs supporting the sector.
XLP presents a defensive investment opportunity with stable dividend income and low volatility characteristics. The fund's concentrated portfolio of essential consumer goods companies provides resilience during market downturns. Key risks include sector rotation away from defensive stocks and potential margin pressure from inflation. Current technical strength and positive analyst sentiment support near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
